CMPS
COMPASS Pathways plc
$11.90
+7.11% 2026-10-20
Healthcare
CMPSSPY
1W
+6.8%
1M
-21.7%
3M
-2.3%
6M
+28.6%
YTD
+72.5%
1Y
+76.3%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsCOMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results
Simply Wall St. · Oct 17
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
Business Wire · Oct 14
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Stocktwits · Oct 10
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 02
COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress
Simply Wall St. · Sep 30
Key stats
Market cap$1.6B
P/E (trailing)–
P/E (forward)-8.3
52-week range4.88 – 15.87
Revenue growth (YoY, latest qtr)–
Dividend yield0.00%
Analyst consensusStrong Buy (16)
Mean price target$23.75 (+100%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-03 · before open · EPS est -0.33
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | -0.33 | -0.36 | -6.6% |
| 2026-05-13 | -0.31 | -0.30 | +3.2% |
| 2026-03-24 | -0.39 | -0.61 | -55.5% |
| 2025-11-04 | -0.40 | -0.38 | +5.3% |
| 2025-07-31 | -0.37 | -0.41 | -11.2% |
| 2025-05-08 | -0.49 | -0.42 | +14.6% |
| 2025-02-27 | -0.64 | -0.63 | +1.8% |
| 2024-10-31 | -0.59 | -0.56 | +4.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
HC Wainwright & Co.
PT $65
2026-08-07 · main
Buy → BuyPT $65
Morgan Stanley
PT $18
2026-08-06 · main
Overweight → OverweightPT $18
RBC Capital
PT $21
2026-08-06 · main
Outperform → OutperformPT $21
B. Riley Securities
PT $22
2026-08-06 · main
Buy → BuyPT $22
Wells Fargo
PT $13
2026-07-27 · init
→ Equal-WeightPT $13
HC Wainwright & Co.
PT $70
2026-07-08 · reit
Buy → BuyPT $70
Insider trades
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:13:42 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.